Thomas N. Krausz to Mesothelioma
This is a "connection" page, showing publications Thomas N. Krausz has written about Mesothelioma.
Connection Strength
2.934
-
Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations. Mod Pathol. 2019 03; 32(3):376-386.
Score: 0.525
-
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. Hum Pathol. 2017 02; 60:86-94.
Score: 0.458
-
BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015 Nov; 46(11):1670-8.
Score: 0.420
-
Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
Score: 0.188
-
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res. 2002 Nov-Dec; 22(6B):3443-8.
Score: 0.174
-
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
Score: 0.168
-
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays. Hum Pathol. 2019 05; 87:11-17.
Score: 0.135
-
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.
Score: 0.125
-
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. Am J Surg Pathol. 2017 Dec; 41(12):1675-1682.
Score: 0.124
-
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018 Jan; 142(1):89-108.
Score: 0.120
-
Evaluation of clonal origin of malignant mesothelioma. J Transl Med. 2014 Dec 04; 12:301.
Score: 0.100
-
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study. Lung Cancer. 2014 Mar; 83(3):324-8.
Score: 0.094
-
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012 Aug 30; 10:179.
Score: 0.086
-
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013 May; 137(5):647-67.
Score: 0.086
-
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009 Aug; 133(8):1317-31.
Score: 0.069
-
Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium. Am J Clin Pathol. 2014 Jul; 142(1):82-7.
Score: 0.024
-
p53 expression is common in malignant mesothelioma. Histopathology. 1992 Oct; 21(4):331-4.
Score: 0.022
-
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12611-6.
Score: 0.018